drugset / Trial / NCT05955391
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2
Active not recruiting
164 enrolled
Shenzhen TargetRx Co., Ltd.
Affiliated Cancer Hospital of Guizhou Medical University · collabBingzhou Medical University Affiliated Hospital · collabCancer Hospital Chinese Academy of Medical Science, Shenzhen Center · collabCapital Medical School Beijing Chest Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabFirst Hospital of China Medical University · collabFujian Cancer Hospital · collabHaerbin Medical University Cancer Hospital · collabHenan Cancer Hospital · collabHunan Cancer Hospital · collabJiangxi Provincial Cancer Hospital · collabJilin Provincial Tumor Hospital · collabJingzhou First People's Hospital · collabLiaoning Cancer Hospital & Institute · collabMianyang Central Hospital · collabNanchang University First Affiliated Hospital · collabNingbo No. 1 Hospital · collabShandong Cancer Hospital and Institute · collabShanghai Chest Hospital · collabShijiazhuang People's Hospital · collabSichuan Cancer Hospital and Research Institute · collabSun Yat-Sen University Cancer Center · collabThe Affiliated Hospital of Qingdao University · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe First Affiliated Hospital of Zhengzhou University · collabThe Second Affiliated Hospital of AFMU · collabTianjin Cancer Hospital · collabTongji Hospital · collabWest China Hospital · collabXiangyang Central Hospital · collabXinxiang Central Hospital · collabYunnan Cancer Hospital · collabZhejiang Cancer Hospital · collabZhejiang University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, single-arm, open-label, Phase II clinical trial which explores the safety and efficacy of TGRX-326 in patients with ALK-positive advanced NSCLC who have failed prior 2nd-generation ALK treatments due to progressive disease or intolerance.
Timeline
- Start
- 2023-01-18
- Primary completion
- 2024-12-29
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGRX-326 | Unknown | 60 mg | — |